Hildur Helgadottir

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

- M.D. University of Iceland. 2002
- Specilist inom onkologi. Karolinska Universitetssjukhuset. 2012
- Ph.D. Karolinska Institutet. 2015
  - Cancer Risks and Prognosis in Familial Melanoma Kindreds
- Ordförande Svenska Melanomstudiegruppen (SMSG)
  - https://www.svenskamelanomstudiegruppen.se/

Forskningsbeskrivning

- Melanomgenetik
- Melanomsjukdomens epidemiologi, prevention och prognos
- Immunterapi, målriktad terapi och strålterapi vid melanom
- Mer info på hemsida: Hildur Helgadottir's Group | Karolinska Institutet
- - https://ki.se/en/onkpat/hildur-helgadottirs-group

Artiklar

Article: EUROPEAN JOURNAL OF CANCER. 2024;202:114010

Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors.

Helgadottir H; Matikas A; Fernebro J; Frödin J-E; Ekman S; Rodriguez-Wallberg KA
Article: ANNALS OF SURGERY. 2024

Survival and Quality of Life after Isolated Hepatic Perfusion with Melphalan as a Treatment for Uveal Melanoma Liver Metastases - Final Results from the Phase III Randomized Controlled Trial SCANDIUM.

Olofsson Bagge R; Nelson A; Shafazand A; All-Eriksson C; Cahlin C; Elander N; Gustavsson A; Helgadottir H; Kiilgaard JF; Kinhult S; Ljuslinder I; Mattsson J; Rizell M; Sternby Eilard M; Ullenhag GJ; Nilsson JA; Ny L; Lindnér P
Article: NATURE COMMUNICATIONS. 2024;15(1):146

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.

Ascierto PA; Casula M; Bulgarelli J; Pisano M; Piccinini C; Piccin L; Cossu A; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance A; Guida M; Maiello E; Gogas H; Richtig E; Fierro MT; Lebbe C; Helgadottir H; Queirolo P; Spagnolo F; Tucci M; Del Vecchio M; Cao MG; Minisini AM; De Placido S; Sanmamed MF; Mallardo D; Paone M; Vitale MG; Melero I; Grimaldi AM; Giannarelli D; Dummer R; Sileni VC; Palmieri G
Article: ACTA ONCOLOGICA. 2023;62(12):1921-1930

Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and tolerability.

Backlund E; Grozman V; Egyhazi Brage S; Lewensohn R; Lindberg K; Helgadottir H
Article: EUROPEAN JOURNAL OF HUMAN GENETICS. 2023;31(11):1261-1269

Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome.

Lalloo F; Kulkarni A; Chau C; Nielsen M; Sheaff M; Steele J; van Doorn R; Wadt K; Hamill M; Torr B; Tischkowitz M; Delphi respondents; Hanson H
Article: JAMA DERMATOLOGY. 2023;159(10):1112-1118

Estimated Prevalence, Tumor Spectrum, and Neurofibromatosis Type 1-Like Phenotype of CDKN2A-Related Melanoma-Astrocytoma Syndrome.

Sargen MR; Kim J; Potjer TP; Velthuizen ME; Martir-Negron AE; Odia Y; Helgadottir H; Hatton JN; Haley JS; Thone G; Widemann BC; Gross AM; Yohe ME; Kaplan RN; Shern JF; Sundby RT; Astiazaran-Symonds E; Yang XR; Carey DJ; Tucker MA; Stewart DR; Goldstein AM
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2023;115(9):1077-1084

Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study.

Helgadottir H; Ny L; Ullenhag GJ; Falkenius J; Mikiver R; Olofsson Bagge R; Isaksson K
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(17_suppl):lba9512

Survival after isolated hepatic perfusion as a treatment for uveal melanoma liver metastases: Results from a randomized controlled trial (the SCANDIUM trial).

Olofsson Bagge R; Nelson A; Shafazand A; All-Eriksson C; Cahlin C; Elander N; Helgadottir H; Kiilgaard JF; Kinhult S; Ljuslinder I; Rizell M; Sternby Eilard M; Ullenhag GJ; Nilsson JA; Ny L; Lindner P
Article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(16):3042-3050

Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).

Olofsson Bagge R; Nelson A; Shafazand A; All-Eriksson C; Cahlin C; Elander N; Helgadottir H; Kiilgaard JF; Kinhult S; Ljuslinder I; Mattsson J; Rizell M; Sternby Eilard M; Ullenhag GJ; Nilsson JA; Ny L; Lindnér P
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(16_suppl):9533

A phase I, randomized, controlled, multicentre trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (the SCANDIUM 2 trial).

Olofsson Bagge R; Nelson A; Shafazand A; Cahlin C; Carneiro A; Helgadottir H; Levin M; Rizell M; Ullenhag GJ; Wirén S; Lindner P; Nilsson JA; Ny L
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(16_suppl):9570

Overall survival after the introduction of adjuvant treatment in stage III melanoma: A nationwide registry based study.

Helgadottir H; Ny L; Ullenhag GJ; Falkenius J; Mikiver R; Olofsson Bagge R; Isaksson K
Article: CANCER RESEARCH COMMUNICATIONS. 2023;3(5):884-895

Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy.

Sah VR; Jespersen H; Karlsson J; Nilsson LM; Bergqvist M; Johansson I; Carneiro A; Helgadottir H; Levin M; Ullenhag G; Ståhlberg A; Olofsson Bagge R; Nilsson JA; Ny L
Article: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023;37(2):284-292

Melanoma-specific survival before and after inclusion in a familial melanoma dermatologic surveillance program in CDKN2A mutation carriers and non-carriers.

Pissa M; Lapins J; Sköldmark C; Helgadottir H
Article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(2):212-221

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.

Ascierto PA; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance A; Guida M; Maiello E; Gogas H; Richtig E; Fierro MT; Lebbè C; Helgadottir H; Queirolo P; Spagnolo F; Tucci M; Del Vecchio M; Gonzales Cao M; Minisini AM; De Placido S; Sanmamed MF; Mallardo D; Curvietto M; Melero I; Palmieri G; Grimaldi AM; Giannarelli D; Dummer R; Chiarion Sileni V
Article: JCO PRECISION ONCOLOGY. 2022;6:e2200145

Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in CDKN2A and Pancreatic Cancer.

Astiazaran-Symonds E; Graham C; Kim J; Tucker MA; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Sampson JN; Zhu B; Bruno W; Queirolo P; Fornarini G; Sciallero S; Carter B; Hicks B; Hutchinson A; Jones K; Stewart DR; Chanock SJ; Freedman ND; Landi MT; Höiom V; Puig S; Gruis N; Yang XR; Ghiorzo P; Goldstein AM
Article: JNCI CANCER SPECTRUM. 2022;6(6):pkac074

Impact of Transcript (p16/p14ARF) Alteration on Cancer Risk in CDKN2A Germline Pathogenic Variant Carriers.

Sargen MR; Helgadottir H; Yang XR; Harland M; Hatton JN; Jones K; Hicks BD; Hutchinson A; Curry M; Tucker MA; Goldstein AM; Pfeiffer RM
Article: EUROPEAN JOURNAL OF CANCER. 2022;169:210-222

The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study.

Holmberg C-J; Ny L; Hieken TJ; Block MS; Carr MJ; Sondak VK; Örtenwall C; Katsarelias D; Dimitriou F; Menzies AM; Saw RP; Rogiers A; Straker RJ; Karakousis G; Applewaite R; Pallan L; Han D; Vetto JT; Gyorki DE; Tie EN; Vitale MG; Ascierto PA; Dummer R; Cohen J; Hui JY; Schachter J; Asher N; Helgadottir H; Chai H; Kroon H; Coventry B; Rothermel LD; Sun J; Carlino MS; Duncan Z; Broman K; Weber J; Lee AY; Berman RS; Teras J; Ollila DW; Long GV; Zager JS; van Akkooi A; Olofsson Bagge R
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(17_suppl):lba9509

Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases, first results from a phase III randomized controlled multicenter trial (the SCANDIUM trial).

Olofsson Bagge R; Nelson A; Shafazand A; All-Ericsson C; Cahlin C; Elander N; Helgadottir H; Kiilgaard JF; Kinhult S; Ljuslinder I; Rizell M; Sternby Eilard M; Ullenhag GJ; Nilsson JA; Ny L; Lindner P
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):9569

The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases: A multicenter cohort study.

Olofsson Bagge R; Holmberg CJ; Hieken TJ; Zager JS; Long GV; Van Akkooi ACJ; Karakousis GC; Pallan L; Vetto JT; Gyorki DE; Ascierto PA; Dummer R; Hui JYC; Schachter J; Helgadottir H; Kroon H; Rothermel LD; Carlino MS; Broman KK; Ny L
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):9535

Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up.

Ascierto PA; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance AM; Guida M; Maiello E; Gogas H; Richtig E; Fierro MT; Lebbe C; Helgadottir H; Melero Bermejo I; Palmieri G; Giannarelli D; Grimaldi AM; Dummer R; Chiarion-Sileni V
Article: CANCERS. 2022;14(4):1040

Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study).

Naeser Y; Helgadottir H; Hansson J; Ingvar C; Elander NO; Flygare P; Nilsson C; Jakobsson F; Valachis A; Papantoniou D; Nordin Danfors A; Johansson H; Sundin A; Brandberg Y; Ullenhag GJ
Article: CANCERS. 2022;14(3):702

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors.

Costa Svedman F; Jalsenius M; Höiom V; Grozman V; Bergqvist M; Söderdahl F; Eriksson H; Rotstein S; Ny L; Ascierto PA; Brage SE; Helgadottir H
Article: LAKARTIDNINGEN. 2021;118:21115

[Overview of immune-related side effects from immune checkpoint inhibitors. Part 1: Gastrointestinal, lung and kidney toxicity].

Villabona Lisa Villabona L; Costa Svedman F; Jovanovic B; Kaneteg B; Eberhardson M; Magin H; Ullenhag G; Blomqvist L; Helgadottir H
Article: GENETICS IN MEDICINE. 2021;23(11):2087-2095

Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia.

Dalmasso B; Pastorino L; Nathan V; Shah NN; Palmer JM; Howlie M; Johansson PA; Freedman ND; Carter BD; Beane-Freeman L; Hicks B; Molven A; Helgadottir H; Sankar A; Tsao H; Stratigos AJ; Helsing P; Van Doorn R; Gruis NA; Visser M; Wadt KAW; Mann G; Holland EA; Nagore E; Potrony M; Puig S; Menin C; Peris K; Fargnoli MC; Calista D; Soufir N; Harland M; Bishop T; Kanetsky PA; Elder DE; Andreotti V; Vanni I; Bruno W; Höiom V; Tucker MA; Yang XR; Andresen PA; Adams DJ; Landi MT; Hayward NK; Goldstein AM; Ghiorzo P; GenoMEL; MelaNostrum consortia
Article: NATURE COMMUNICATIONS. 2021;12(1):5155

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma.

Ny L; Jespersen H; Karlsson J; Alsén S; Filges S; All-Eriksson C; Andersson B; Carneiro A; Helgadottir H; Levin M; Ljuslinder I; Olofsson Bagge R; Sah VR; Stierner U; Ståhlberg A; Ullenhag G; Nilsson LM; Nilsson JA
Article: ACTA ONCOLOGICA. 2021;60(7):888-896

CDKN2A genetic testing in melanoma-prone families in Sweden in the years 2015-2020: implications for novel national recommendations.

Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
Article: CANCERS. 2021;13(10):2440

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants.

Spagnolo F; Dalmasso B; Tanda E; Potrony M; Puig S; van Doorn R; Kapiteijn E; Queirolo P; Helgadottir H; Ghiorzo P
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2021;113(3):318-328

Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study.

Helgadottir H; Isaksson K; Fritz I; Ingvar C; Lapins J; Höiom V; Newton-Bishop J; Olsson H
Article: BMC CANCER. 2020;20(1):1197

TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma.

Naeser Y; Helgadottir H; Brandberg Y; Hansson J; Bagge RO; Elander NO; Ingvar C; Isaksson K; Flygare P; Nilsson C; Jakobsson F; Del Val Munoz O; Valachis A; Jansson M; Sparring C; Ohlsson L; Dyrke U; Papantoniou D; Sundin A; Ullenhag GJ
Article: JOURNAL OF MEDICAL GENETICS. 2020;57(5):316-321

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations.

Helgadottir H; Ghiorzo P; van Doorn R; Puig S; Levin M; Kefford R; Lauss M; Queirolo P; Pastorino L; Kapiteijn E; Potrony M; Carrera C; Olsson H; Höiom V; Jönsson G
Article: BMC CANCER. 2019;19(1):415

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.

Jespersen H; Olofsson Bagge R; Ullenhag G; Carneiro A; Helgadottir H; Ljuslinder I; Levin M; All-Eriksson C; Andersson B; Stierner U; Nilsson LM; Nilsson JA; Ny L
Journal article: EJSO. 2019;45(2):e151

Sentinel node biopsy in cutaneous melanoma patients with germline CDKN2A mutation

Ipenburg N; Van der Hage J; Kukutsch N; Helgadottir H; Nieweg O; Vermeer M; Van Doorn R
Article: JOURNAL OF MEDICAL GENETICS. 2018;55(10):661-668

CM-Score: a validated scoring system to predict CDKN2A germline mutations in melanoma families from Northern Europe.

Potjer TP; Helgadottir H; Leenheer M; van der Stoep N; Gruis NA; Höiom V; Olsson H; van Doorn R; Vasen HFA; van Asperen CJ; Dekkers OM; Hes FJ; Dutch Working Group for Clinical Oncogenetics
Article: GENETICS IN MEDICINE. 2018;20(9):1087-1090

Phenocopies in melanoma-prone families with germ-line CDKN2A mutations.

Helgadottir H; Olsson H; Tucker MA; Yang XR; Höiom V; Goldstein AM
Article: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2017;77(5):893-901

Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.

Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
Article: LAKARTIDNINGEN. 2017;114:ELAM

[Increased knowledge on familial melanoma and the underlying genetics].

Helgadottir H; Nielsen K; Höiom V
Article: HUMAN GENETICS. 2016;135(11):1241-1249

Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.

Yang XR; Rotunno M; Xiao Y; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Bennett H; Graham C; Sampson JN; Malasky M; Vogt A; Zhu B; Bianchi-Scarra G; Bruno W; Queirolo P; Fornarini G; Hansson J; Tuominen R; Burdett L; Hicks B; Hutchinson A; Jones K; Yeager M; Chanock SJ; Landi MT; Höiom V; Olsson H; Gruis N; Ghiorzo P; Tucker MA; Goldstein AM
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2016;108(11):djw135

Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.

Helgadottir H; Höiom V; Tuominen R; Nielsen K; Jönsson G; Olsson H; Hansson J
Article: GENES CHROMOSOMES & CANCER. 2016;55(7):601-611

The role of germline alterations in the DNA damage response genes BRIP1 and BRCA2 in melanoma susceptibility.

Tuominen R; Engström PG; Helgadottir H; Eriksson H; Unneberg P; Kjellqvist S; Yang M; Lindén D; Edsgärd D; Hansson J; Höiom V
Article: INTERNATIONAL JOURNAL OF CANCER. 2015;137(9):2220-2226

CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.

Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
Article: JOURNAL OF MEDICAL GENETICS. 2014;51(8):545-552

High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families.

Helgadottir H; Höiom V; Jönsson G; Tuominen R; Ingvar C; Borg A; Olsson H; Hansson J
Article: GENES CHROMOSOMES & CANCER. 2013;52(4):378-384

Hereditary uveal melanoma: a report of a germline mutation in BAP1.

Höiom V; Edsgärd D; Helgadottir H; Eriksson H; All-Ericsson C; Tuominen R; Ivanova I; Lundeberg J; Emanuelsson O; Hansson J
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(15_suppl):10521

BAP1 : The first mutated gene causing familial uveal melanoma.

Hansson J; All-Eriksson C; Helgadottir H; Edsgard D; Tuominen R; Lundeberg J; Ivanova I; Emanuelsson O; Hoiom V
Journal article: JOURNAL OF NUCLEIC ACIDS INVESTIGATION. 2010;1(1):9

Survival of the fittest or best adapted: HLA-dependent tumor development

Masucci GV; Andersson E; Villabona L; Helgadottir H; Bergfeldt K; Cavallo F; Forni G; Ferrone S; Choudhury A; Seliger B; Kiessling R
Journal article: JOURNAL OF NUCLEIC ACIDS INVESTIGATION. 2010;1(1):9

Survival of the fittest or best adapted: HLA-dependent tumor development

Masucci GV; Andersson E; Villabona L; Helgadottir H; Bergfeldt K; Cavallo F; Forni G; Ferrone S; Choudhury A; Seliger B; Kiessling R
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2009;58(10):1599-1608

The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma.

Helgadottir H; Andersson E; Villabona L; Kanter L; van der Zanden H; Haasnoot GW; Seliger B; Bergfeldt K; Hansson J; Ragnarsson-Olding B; Kiessling R; Masucci GV
Article: BLOOD. 2009;113(15):3461-3471

Mef2C is a lineage-restricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis.

Gekas C; Rhodes KE; Gereige LM; Helgadottir H; Ferrari R; Kurdistani SK; Montecino-Rodriguez E; Bassel-Duby R; Olson E; Krivtsov AV; Armstrong S; Orkin SH; Pellegrini M; Mikkola HKA
Journal article: BLOOD. 2008;112(11):278

Mef2C Is a Lineage-Restricted Target Gene of Scl/Tal1 and Regulates Megakaryopoiesis and B-Cell Homeostasis

Rhodes KE; Gekas C; Gereige L; Helgadottir H; Ferrari R; Kurdistani S; Montecino-Rodriguez E; Basel-Duby R; Olson E; Orkin SH; Pellegrini M; Mikkola H
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2005;102(41):14789-14794

Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients.

Hakonarson H; Bjornsdottir US; Halapi E; Bradfield J; Zink F; Mouy M; Helgadottir H; Gudmundsdottir AS; Andrason H; Adalsteinsdottir AE; Kristjansson K; Birkisson I; Arnason T; Andresdottir M; Gislason D; Gislason T; Gulcher JR; Stefansson K
Article: BLOOD. 2005;105(10):3871-3874

Tie2Cre-mediated gene ablation defines the stem-cell leukemia gene (SCL/tal1)-dependent window during hematopoietic stem-cell development.

Schlaeger TM; Mikkola HKA; Gekas C; Helgadottir HB; Orkin SH
Article: BLOOD. 2003;102(9):3129-3135

TGF-beta signaling-deficient hematopoietic stem cells have normal self-renewal and regenerative ability in vivo despite increased proliferative capacity in vitro.

Larsson J; Blank U; Helgadottir H; Björnsson JM; Ehinger M; Goumans M-J; Fan X; Levéen P; Karlsson S
Journal article: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2002;109(1):s173

Asthmatic patients exhibit different gene expression profiles, depending on their sensitivity to glucocorticoids

Helgadóttir H; Bjornsdottir US; Halapi E; Gudmundsdottir AS; Arnason T; Birkisson I; Adalsteinsdottir AA; Ingvarsson S; Andresdottir M; Gislason D; Gislason T; Gulcher J; Stefansson K; Hakonarson H
Article: JOURNAL OF VIROLOGY. 2000;74(24):11911-11918

Lentivirus gene transfer in murine hematopoietic progenitor cells is compromised by a delay in proviral integration and results in transduction mosaicism and heterogeneous gene expression in progeny cells.

Mikkola H; Woods NB; Sjögren M; Helgadottir H; Hamaguchi I; Jacobsen SE; Trono D; Karlsson S
Visa fler

Alla övriga publikationer

Letter: ACTA ONCOLOGICA. 2023;62(12):1967-1972

Familial features affecting the melanoma risk in CDKN2A-negative melanoma families: a study based on the Swedish Cancer Registry.

Helgadottir H; Schultz K; Lapins J; Höiom V
Meeting abstract: ANNALS OF ONCOLOGY. 2023;34:s653

Brain metastases and survival evaluation in the SECOMBIT trial

Ascierto PA; Mandala M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance Fernandez AM; Guida M; Maiello E; Gogas H; Richtig E; Fierro MT; Lebbe C; Helgadottir H; Melero I; Palmieri G; Giannarelli D; Grimaldi AM; Dummer R; Chiarion Sileni V
Letter: ACTA ONCOLOGICA. 2023;62(6):565-570

BAP1 genetic testing among melanoma and cancer-prone families in Sweden.

Helgadottir H; Schultz K; Lapins J; Vassilaki I; All-Eriksson C; Höiom V
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(16)

Overall survival after the introduction of adjuvant treatment in stage III melanoma: A nationwide registry based study

Helgadottir H; Ny L; Ullenhag GJ; Falkenius J; Mikiver R; Bagge RO; Isaksson K
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(16)

A phase I, randomized, controlled, multicentre trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (the SCANDIUM 2 trial).

Bagge RO; Nelson A; Shafazand A; Cahlin C; Carneiro A; Helgadottir H; Levin M; Rizell M; Ullenhag GJ; Wiren S; Lindner P; Nilsson JA; Ny L
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(17)

Survival after isolated hepatic perfusion as a treatment for uveal melanoma liver metastases: Results from a randomized controlled trial (the SCANDIUM trial)

Bagge RO; Nelson A; Shafazand A; All-Eriksson C; Cahlin C; Elander N; Helgadottir H; Kiilgaard JF; Kinhult S; Ljuslinder I; Rizell M; Eilard MS; Ullenhag GJ; Nilsson JA; Ny L; Lindner P
Letter: ACTA ONCOLOGICA. 2022;61(9):1116-1120

Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy.

Costa Svedman F; Jalsenius M; Grozman V; Bergqvist M; Söderdahl F; Rotstein S; Ny L; Egyhazi Brage S; Helgadottir H
Meeting abstract: ANNALS OF ONCOLOGY. 2022;33(7):S1408-S1409

Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation

Ascierto PA; Mandala M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance Fernandez AM; Guida M; Maiello E; Gogas HJ; Richtig E; Fierro MT; Lebbe C; Helgadottir H; Melero I; Palmieri G; Giannarelli D; Grimaldi AM; Dummer R; Sileni VC
Meeting abstract: ANNALS OF ONCOLOGY. 2022;33(7):S945

Inflammation proteins associated with worse clinical outcome to treatment with anti-PD1 in metastatic cutaneous melanoma

Svedman FC; Helgadottir H; Brage SE
Letter: ACTA ONCOLOGICA. 2022;61(7):869-873

Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial.

Backlund E; Yang M; Grozman V; Masucci G; Falkenius J; Eriksson H; Jovanovic B; Hammarlund K; Isacsson U; Radu C; Abel E; Karlsson K; Palanco Zamora R; Wersäll P; Edbäck U; Wickström S; Darai Ramqvist E; Egyhazi Brage S; Kiessling R; Viktorsson K; Franzén B; Lewensohn R; Olofsson Bagge R; Ullenhag GJ; Ny L; Lindberg K; Helgadottir H
Editorial comment: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022;36(2):167-168

Melanoma susceptibility genes in paediatric melanoma and differences in children or adolescents and sporadic or familial cases.

Helgadottir H
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)

The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases: A multicenter cohort study.

Bagge RO; Holmberg CJ; Hieken TJ; Zager JS; Long GV; Van Akkooi ACJ; Karakousis GC; Pallan L; Vetto JT; Gyorki DE; Ascierto PA; Dummer R; Hui JYC; Schachter J; Helgadottir H; Kroon H; Rothermel LD; Carlino MS; Broman KK; Ny L
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)

Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up.

Ascierto PA; Mandala M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance AM; Guida M; Maiello E; Gogas H; Richtig E; Fierro MT; Lebbe C; Helgadottir H; Bermejo IM; Palmieri G; Giannarelli D; Grimaldi AM; Dummer R; Chiarion-Sileni V
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(17)

Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases, first results from a phase III randomized controlled multicenter trial (the SCANDIUM trial).

Bagge RO; Nelson A; Shafazand A; All-Ericsson C; Cahlin C; Elander N; Helgadottir H; Kiilgaard JF; Kinhult S; Ljuslinder I; Rizell M; Eilard MS; Ullenhag GJ; Nilsson JA; Ny L; Lindner P
Review: LAKARTIDNINGEN. 2021;118:21114

[Overview of immune-related side effects from immune checkpoint inhibitors. Part 2: Endocrine, rheumatologic and skin toxicity].

Helgadottir H; Falkenius J; Eriksson H; Girnita A; Sahlberg L; Bensing S; Chatzidionysiou K; Masucci G; Ullenhag G
Meeting abstract: ANNALS OF ONCOLOGY. 2021;32:s1316-s1317

SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study

Ascierto PA; Mandala M; Ferrucci PF; Rutkowski P; Guidoboni M; Fernandez AMA; Ferraresi V; Maiello E; Guida M; Del Vecchio M; Fierro MT; Queirolo P; Lebbe C; Helgadottir H; Melero I; Palmieri G; Giannarelli D; Grimaldi AM; Dummer R; Sileni VC
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2021;39(15):9556

Plasma thymidine kinase activity (TKa) as a novel prognostic biomarker in metastatic melanoma.

Helgadottir H; Svedman FC; Jalsenius M; Hoiom V; Rotstein S; Brage SE; Grozman V; Soderdahl F; Ny L; Bergqvist M
Letter: ACTA ONCOLOGICA. 2021;60(1):52-55

Surgery of metastatic melanoma after systemic therapy - the SUMMIST trial: study protocol for a randomized controlled trial.

Holmberg CJ; Katsarelias D; Jespersen H; Carneiro A; Elander NO; Helgadottir H; Isaksson K; Jansson M; Wirén S; Ullenhag GJ; Ny L; Olofsson Bagge R
Letter: MELANOMA RESEARCH. 2020;30(6):630-631

Sentinel node biopsy in cutaneous melanoma patients with germline CDKN2A mutations.

Ipenburg NA; van der Hage JA; Newton-Bishop JA; Harland M; Kukutsch NA; Helgadottir H; Vermeer MH; Nieweg OE; van Doorn R
Meeting abstract: ANNALS OF ONCOLOGY. 2020;31:S1173-S1174

First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)

Ascierto PA; Mandala M; Ferrucci PF; Rutkowski P; Guidoboni M; Arance Fernandez AM; Ferraresi V; Maiello E; Guida M; Del Vecchio M; Fierro MT; Queirolo P; Lebbe C; Helgadottir H; Melero I; Palmieri G; Giannarelli D; Grimaldi AM; Dummer R; Sileni VC
Meeting abstract: ANNALS OF ONCOLOGY. 2020;31:S759

BRAF and MEK inhibition in CDKN2A germline carriers and BRAF mutant melanoma

Spagnolo F; Dalmasso B; Helgadottir H; Hoiom V; van Doorn R; Kapiteijn E; Potrony M; Puig S; Queirolo P; Ghiorzo P
Meeting abstract: ANNALS OF ONCOLOGY. 2020;31:S766

Multiple primary melanoma incidence trends over five decades, a nationwide population-based study

Helgadottir H; Isaksson K; Fritz I; Ingvar C; Lapins J; Hoiom V; Newton-Bishop J; Olsson H
Conference publication: JOURNAL OF TRANSLATIONAL MEDICINE. 2019;17

Efficacy of novel melanoma treatments in metastatic melanoma patients with germline CDKN2A mutations

Helgadottir H; Ghiorzo P; van Doorn R; Puig S; Levin M; Kefford R; Queirolo P; Pastorino L; Lauss M; Olsson H; Hoiom V; Jonsson G
Conference publication: ANNALS OF ONCOLOGY. 2019;30:907

Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study)

Jespersen H; Bagge RO; Ullenhag G; Carneiro A; Helgadottir H; Ljuslinder I; Levin M; All-Eriksson C; Andersson B; Stierner U; Nilsson LM; Nilsson JA; Ny L
Review: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(12):1328-1341

Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.

Walpole S; Pritchard AL; Cebulla CM; Pilarski R; Stautberg M; Davidorf FH; de la Fouchardière A; Cabaret O; Golmard L; Stoppa-Lyonnet D; Garfield E; Njauw C-N; Cheung M; Turunen JA; Repo P; Järvinen R-S; van Doorn R; Jager MJ; Luyten GPM; Marinkovic M; Chau C; Potrony M; Höiom V; Helgadottir H; Pastorino L; Bruno W; Andreotti V; Dalmasso B; Ciccarese G; Queirolo P; Mastracci L; Wadt K; Kiilgaard JF; Speicher MR; van Poppelen N; Kilic E; Al-Jamal RT; Dianzani I; Betti M; Bergmann C; Santagata S; Dahiya S; Taibjee S; Burke J; Poplawski N; O'Shea SJ; Newton-Bishop J; Adlard J; Adams DJ; Lane A-M; Kim I; Klebe S; Racher H; Harbour JW; Nickerson ML; Murali R; Palmer JM; Howlie M; Symmons J; Hamilton H; Warrier S; Glasson W; Johansson P; Robles-Espinoza CD; Ossio R; de Klein A; Puig S; Ghiorzo P; Nielsen M; Kivelä TT; Tsao H; Testa JR; Gerami P; Stern M-H; Paillerets BB-D; Abdel-Rahman MH; Hayward NK
Review: FRONTIERS IN ONCOLOGY. 2018;8:202

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

Helgadottir H; Rocha Trocoli Drakensjö I; Girnita A
Letter: ANNALS OF ONCOLOGY. 2017;28(7):1672-1673

Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.

Helgadottir H; Kis L; Ljungman P; Larkin J; Kefford R; Ascierto PA; Hansson J; Masucci G
Letter: LAKARTIDNINGEN. 2017;114:ELAP

[The melanoma incidence continues to rise].

Helgadottir H; Stierner U
Review: APPLICATION OF CLINICAL GENETICS. 2016;9:147-155

The genetics of uveal melanoma: current insights.

Helgadottir H; Höiom V
Thesis / dissertation: 2015

Cancer risks and prognosis in familial melanoma kindreds

Helgadóttir, Hildur Björg
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(15):1513

Risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families.

Helgadottir H; Heim V; Jonsson G; Tuominen R; Ingvar C; Borg A; Olsson HL; Hansson J
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(15)

BAP1: The first mutated gene causing familial uveal melanoma

Hansson J; All-Eriksson C; Helgadottir H; Edsgard D; Tuominen R; Lundeberg J; Ivanova I; Emanuelsson O; Hoiom V
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(15):9050

Ancestral HLA haplotypes 62.1 and 8.1 as negative prognostic factors in patients with metastatic malignant melanoma

Helgadottir H; Andersson E; Hansson J; Kiessling R; Masucci GV
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(15):16544

Survival rates in HLA-A2 positive patients, with stage III-IV serous adenocarcinomas of the ovary, correlates with increased expression of COX-2 and iNOS, loss of MHC Class I and II and defects of the antigen processing mechanisms at the tumour level

Andersson E; Johansson CC; Villabona L; Kanter L; Helgadottir H; Dalianis T; Bergfeldt K; Seliger B; Ferrone S; Kiessling R; Masucci GV
Conference publication: BLOOD. 2008;112(11):109

Mef2C Is a Lineage-Restricted Target Gene of Scl/Tal1 and Regulates Megakaryopoiesis and B-Cell Homeostasis

Rhodes KE; Gekas C; Gereige L; Helgadottir H; Ferrari R; Kurdistani S; Montecino-Rodriguez E; Basel-Duby R; Olson E; Orkin SH; Pellegrini M; Mikkola H
Conference publication: EXPERIMENTAL HEMATOLOGY. 2008;36(7):S29

Transcription factor MEF2C is a putative target gene of SCL/tal1 with unique and overlapping requirements in hematopoiesis

Gekas C; Rhodes K; Helgadottir H; Bassel-Duby RS; Olson EN; Orkin SH; Pellegrini M; Mikkola HKA
Conference publication: EXPERIMENTAL HEMATOLOGY. 2008;36(7):S22

Transcription factor MEF2C is a putative target gene of SCL/tal1 with unique and overlapping requirements in hematopoiesis

Gekas C; Rhodes K; Helgadottir H; Bassel-Duby RS; Olson EN; Orkin SH; Pellegrini M; Mikkola HKA
Meeting abstract: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2002;109(1):s174

A potential role for genes in asthma independent of atopy

Bjornsdottir US; Helgadóttir H; Halapi E; Adalsteinsdottir E; Gudmundsdottir AS; Birkisson I; Arnason T; Ingvarsson S; Andresdottir M; Gislason D; Gislason T; Gulcher J; Stefansson K; Hakonarson H
Conference publication: BLOOD. 2000;96(11):821A

A critical role for TGF-β signalling in preventing exhaustion of hematopoietic stem cells in vivo.

Larsson J; Helgadottir H; Levéen P; Karlsson S
Conference publication: BLOOD. 2000;96(11):588A-589A

Efficient lentiviral gene transfer into murine hematopoietic stem cells and stable expression of the lentiviral transgene in myeloid and lymphoid cells of serially transplanted mice.

Mikkola H; Helgadottir H; Woods NB; Salmon P; Trono D; Karlsson S
Conference publication: BLOOD. 1999;94(10):356A

Lentiviral gene transfer and expression in c-kit+sca1+mouse hematopoietic stem cells.

Mikkola H; Helgadottir H; Woods NB; Hamaguchi I; Zufferey R; Jacobsen SE; Trono D; Karlsson S
Visa fler

Anställningar

Senior Forskningsspecialist, Onkologi-Patologi, Karolinska Institutet, 2023-

Examina och utbildning

Docent, Cancer och onkologi, Karolinska Institutet, 2023
Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2016

Om mig

Forskningsbeskrivning

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI